stockrow
Friday 6 November 2026
Export PTN’s income statement to Excel — free account
Palatin Technologies, Inc.
Palatin Technologies, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $13.2 million, up 193.6% from fiscal 2024.
- Revenue
- −14.1%
- EPS
- +59.3%
- Free cash flow
- +34.2%
Quarter to June 2026, against a year earlier
5.74
0.28
−4.65%
Follow PTN
Alert me
Palatin Technologies, Inc. (PTN) P/E ratio
As of 5 November 2026, Palatin Technologies, Inc. (PTN) trades at a P/E ratio of 12.2×. Over the past ten years it has ranged from 0.0× (June 2026) to 161× (March 2019); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 10.3× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 23.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 6.4× | (20.43%) |
| FY2018 | 8.1× | — |
| FY2017 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 23.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 26 more quarters | Free account |
Against its own ten years
Low 0.0×
High 161×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| BIVI BioVie Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| AZR Azora Therapeutics, Inc. compare | n/m |
| PTN Palatin Technologies, Inc. | 12.2× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)